

Reference: FOI.ICB-2526/295

Subject: Tirzepatide/Mounjaro Prescribing

I can confirm that the ICB does hold the information requested; please see responses below:

| QUESTION | RESPONSE |
|--|---|
| <ol style="list-style-type: none"> Has the ICB started prescribing Tirzepatide/Mounjaro in line with the NICE Technology Appraisal TA1026 and the NICE funding variation for tirzepatide (Mounjaro) for the management of obesity? If yes, how are patients accessing the treatment? E.g. through their GP or a specialist service. If yes, how much has the ICB so far spent on tirzepatide for the management of obesity? If no, is there a planned start date? If no, what is causing the delay? | <ol style="list-style-type: none"> Yes. GP – as per NICE funding variation NHSE commissioning guidance Commissioned specialist weight management services – as per NICE TA1026 Total = £86,557 Tirzepatide drug spend from GP prescribing to patients with the code of NHS obesity medication pathway started from 1/7/25 – 4/12/25 is £77,273 Tirzepatide drug spend from specialist service to month 5 26/27 (August 25) is £9,284 n/a n/a |

The information provided in this response is accurate as of 12 December 2025 and has been approved for release by Dr Joanne Medhurst, Chief Medical Officer for NHS Bristol, North Somerset and South Gloucestershire ICB.